Test Id : DMITO

For skin biopsy or cultured fibroblast specimens, fibroblast culture testing will be performed at an additional charge. If viable cells are not obtained, the client will be notified.

For diagnosis of a mitochondrial DNA deletion syndrome, the recommended first tier test is MITOP/ Mitochondrial Full Genome Analysis, Next-Generation Sequencing (NGS), Varies.

Specimen preferred to arrive within 96 hours of collection.

Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

Submit only 1 of the following specimens:

Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA) or yellow top (ACD)

Acceptable: Any anticoagulant

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot.

Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated

Specimen Type: Cultured fibroblasts

Container/Tube: T-25 flask

Specimen Volume: 2 Flasks

Collection Instructions: Submit confluent cultured fibroblast cells from a skin biopsy. Cultured cells from a prenatal specimen will not be accepted.

Specimen Stability Information: Ambient (preferred)/Refrigerated (<24 hours)

Additional Information: A separate culture charge will be assessed under CULFB / Fibroblast Culture for Biochemical or Molecular Testing. An additional 3 to 4 weeks is required to culture fibroblasts before genetic testing can occur.

Specimen Type: Skin biopsy

Supplies: Fibroblast Biopsy Transport Media (T115)

Container/Tube: Sterile container with any standard cell culture media (eg, minimal essential media, RPMI 1640). The solution should be supplemented with 1% penicillin and streptomycin.

Specimen Volume: 4-mm punch

Specimen Stability Information: Refrigerated (preferred)/Ambient

Additional Information: A separate culture charge will be assessed under CULFB / Fibroblast Culture for Biochemical or Molecular Testing. An additional 3 to 4 weeks is required to culture fibroblasts before genetic testing can occur.

Specimen Type: Muscle tissue biopsy

Supplies: Muscle Biopsy Kit (T541)

Collection Instructions: Prepare and transport specimen per instructions in Muscle Biopsy Specimen Preparation Instructions.

Specimen Volume: 10-80 mg

Specimen Stability Information: Frozen (preferred)/Ambient/Refrigerated

Specimen Type: Snap frozen nerve tissue biopsy

Collection Instructions: Prepare snap frozen tissue biopsy per surgical procedure

Specimen Volume: 0.25-0.5 cm

Specimen Stability Information: Frozen

Specimen Type: Blood spot

Supplies: Card-Blood Spot Collection (Filter Paper) (T493)

Container/Tube:

Preferred: Collection card (Whatman Protein Saver 903 Paper)

Acceptable: PerkinElmer 226 (formerly Ahlstrom 226) filter paper, or blood spot collection card

Specimen Volume: 2 to 5 Blood spots

Collection Instructions:

1. An alternative blood collection option for a patient older than 1 year is a fingerstick. For detailed instructions, see How to Collect Dried Blood Spot Samples.

2. Let blood dry on the filter paper at ambient temperature in a horizontal position for a minimum of 3 hours.

3. Do not expose specimen to heat or direct sunlight.

4. Do not stack wet specimens.

5. Keep specimen dry.

Specimen Stability Information: Ambient (preferred)/Refrigerated

Additional Information:

1. Due to lower concentration of DNA yielded from blood spot, it is possible that additional specimen may be required to complete testing.

2. For collection instructions, see Blood Spot Collection Instructions.

3. For collection instructions in Spanish, see Blood Spot Collection Card-Spanish Instructions (T777).

4. For collection instructions in Chinese, see Blood Spot Collection Card-Chinese Instructions (T800).

• Muscle Biopsy Specimen Preparation Instructions
• Molecular Genetics: Biochemical Disorders Patient Information
• Informed Consent for Genetic Testing
• Blood Spot Collection Card-Spanish Instructions
• Blood Spot Collection Card-Chinese Instructions
• Informed Consent for Genetic Testing (Spanish)
• Blood Spot Collection Instructions

1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing (Spanish) (T826)

2. Molecular Genetics: Biochemical Disorders Patient Information (T527)

3. If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

-Neurology Specialty Testing Client Test Request (T732)

-Biochemical Genetics Test Request (T798)

Blood: 1 mL; Blood spots: 2 spots; Other specimen types: See Specimen Required

Assessing the heteroplasmy level of previously detected large mitochondrial DNA (mtDNA) deletions.

Screening family members for previously detected large mtDNA deletions.

This test is not recommended for first tier diagnostic testing for mitochondrial disorders.

This test does not assess mtDNA depletion.

This test utilizes droplet digital polymerase chain reaction (ddPCR) for confirmation and determination of heteroplasmy levels of previously detected large mitochondrial DNA (mtDNA) deletions.

Identification of heteroplasmy for large mtDNA deletions may assist with the diagnosis, prognosis, clinical management, recurrence risk assessment, familial screening, and genetic counseling for mtDNA deletion syndromes.

For skin biopsy or cultured fibroblast specimens, fibroblast culture testing will be performed at an additional charge. If viable cells are not obtained, the client will be notified.

Large deletions in the mitochondrial genome (mtDNA deletions) cause up to 10% of primary mitochondrial disease.(1) mtDNA deletions typically present with 1 of 3 syndromes, but a large amount of clinical overlap exists. The 3 syndromes include Kearns-Sayre syndrome, Pearson syndrome, and progressive external ophthalmoplegia (PEO). Occasionally large mtDNA deletions may cause Leigh syndrome. The phenotypes for these conditions vary.

Kearns-Sayre syndrome typically has an age of onset of less than 20 years and is characterized by pigmentary retinopathy or PEO, cardiac conduction defects, ataxia, and an increased spinal fluid (CSF) protein level. A common, recurrent deletion spanning m.8470_13446 causes Kearns-Sayre syndrome; however, there are additional deletions that contribute to the syndrome. These deletions are detected in muscle.

Pearson syndrome's clinical features include sideroblastic anemia, exocrine pancreas dysfunction with symptoms in the first year of life. mtDNA deletions that cause Pearson syndrome are abundant in blood.

Chronic PEO can be the mildest of the mtDNA deletion phenotypes. This presentation is characterized by progressive ptosis, ophthalmoplegia, oropharyngeal, and proximal muscle weakness. mtDNA deletions that cause PEO are primarily detectable in muscle.

Occasionally, mtDNA deletions cause Leigh syndrome, which is characterized by psychomotor regression, abnormal brain MRI, and elevated blood and CSF lactate levels. However, other mtDNA variants may also cause Leigh syndrome. If caused by a large deletion, it is usually detectable in muscle or blood.

Large deletions can be present in only a fraction of mitochondria; a phenomenon known as heteroplasmy. Typically, the severity of disease presentation is a function of the degree of heteroplasmy. Determining the heteroplasmy of large mtDNA deletions is challenging by common clinical methods, such as next-generation sequencing. However, this droplet digital polymerase chain reaction method can obtain an accurate range of heteroplasmy levels in a variety of tissues.

An interpretive report will be provided.

The interpretation of molecular biomarker analysis includes an overview of the results and the associated diagnostic, prognostic, and therapeutic implications.

Clinical Correlations:

Test results should be interpreted in context of clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

If testing was performed because of a clinically significant family history, it is often useful to first test an affected family member. Detection of a reportable variant in an affected family member would allow for more informative testing of at-risk individuals.

Technical Limitations:

This assay will not detect the breakpoints for large mitochondrial deletions or single nucleotide variants that cause mitochondrial disease. Therefore, the absence of a detectable variant does not rule out the possibility that an individual is affected with mitochondrial disease. This test can only detect mitochondrial DNA (mtDNA) deletions that include the mt-ND4 or mt-ND2 genes.

Some individuals who have a mitochondrial deletion syndrome may have a deletion that is not identified by this assay. The absence of a deletion, therefore, does not eliminate the possibility of a mitochondrial DNA deletion syndrome. For predictive testing of asymptomatic individuals, it is important to first document the presence of a deletion in an affected family member.

Of note, absence of a mitochondrial deletion does not rule out the presence of a deletion below the limits of detection of this assay (<10% heteroplasmy).

Rare variants exist that could lead to false-negative or false-positive results. If results obtained do not match clinical findings, additional testing should be considered.

1. Lamont PJ, Surtees R, Woodward CE, Leonard JV, Wood NW, Harding AE. Clinical and laboratory findings in referrals for mitochondrial DNA analysis. Arch Dis Child. 1998;79(1):22-27. doi:10.1136/adc.79.1.22

2. Goldstein A, Falk MJ. Mitochondrial DNA deletion syndromes. In: Adam MP, Mirzaa GM, Pagon RA, et al, eds. GeneReviews [Internet]. University of Washington, Seattle; 2003. Updated May 11, 2023. Accessed June 30, 2023. Available at www.ncbi.nlm.nih.gov/books/NBK1203/

3. Legati A, Zanetti N, Nasca A, et al. Current and new next-generation sequencing approaches to study mitochondrial DNA. J Mol Diagn. 2021;23(6), 732-741

4. McCormick EM, Lott MT, Dulik MC, et al. Specifications of the ACMG/AMP standards and guidelines for mitochondrial DNA variant interpretation. Hum Mutat. 2020;41(12):2028-2057

This test is a droplet digital polymerase chain reaction method for determining heteroplasmy for large mitochondrial genome deletions.(Unpublished Mayo method)

Monday through Friday

• Authorized users can sign in to Test Prices for detailed fee information.
• Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
• Prospective clients should contact their account representative. For assistance, contact Customer Service.

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

81479